ZAI LAB LIMITED Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ZAI LAB LIMITED (ZLAB) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $36.82 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2025-02-27
- ZAI LAB LIMITED valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $36.82M, a 50.16% decline from fiscal 2023.
- ZAI LAB LIMITED valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $73.88M, a 21.72% decline from fiscal 2022.
- ZAI LAB LIMITED valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $94.39M, a 11.64% increase from fiscal 2021.
- ZAI LAB LIMITED valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $84.55M, a 101.70% increase from fiscal 2020.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|---|
| 2024-12-31 | $36.82M 10-K · filed 2025-02-27 | ||
| 2023-12-31 | $73.88M 10-K · filed 2025-02-27 | ||
| 2022-12-31 | $94.39M 10-K · filed 2024-02-27 | ||
| 2021-12-31 | $84.55M 10-K · filed 2023-03-01 | ||
| 2020-12-31 | $41.92M 10-K · filed 2022-03-01 | ||
| 2020-06-30 | $41.71M 6-K · filed 2020-09-11 | ||
| 2019-12-31 | $13.29M 10-K · filed 2021-03-01 | ||
| 2019-06-30 | $16.47M 6-K · filed 2020-09-11 | ||
| 2018-12-31 | $32.66M 20-F · filed 2020-04-29 | $32.66M 20-F · filed 2019-03-29 | |
| 2017-12-31 | $9.01M 20-F · filed 2019-03-29 | ||
| 2016-12-31 | $6.44M 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |